Medannex is pioneering the targeting of annexin-A1 to provide powerful new treatment options for people impacted by cancers and autoimmune diseases. Annexin-A1 drives cancer cell growth and migration and also plays a key role in the development of several autoimmune conditions. Extensive pre-clinical data demonstrate that our first-in-class monoclonal antibody therapeutic (MDX-124) effectively blocks the action of annexin-A1. A Phase 1b clinical study is under way, in cancer patients. In parallel, we are currently preparing for further clinical studies in autoimmune diseases.
Company Details
- Employees
- 12
- Founded
- -
- Address
- 1 Lochrin Square, Fountainbridge,united Kingdom
- Phone
- +44(0)1313574251
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- medannex.org
- Keywords
- Antibody development, Innovation, Biotechnology, T cell modulation, Skills development, Autoimmune diseases, Inflammation, Lupus, SLE, Collaboration, Research, cancer, oncology.
- HQ
- EDINBURGH, MIDLOTHIAN
Medannex Ltd Questions
Medannex Ltd's helpline number is +44(0)1313574251
Medannex Ltd's website is medannex.org
Medannex Ltd's LinkedIn profile is https://uk.linkedin.com/company/medannex-limited
Medannex Ltd has
12 employees.
View email and phone details for 12
employees at Medannex Ltd.
Medannex Ltd's industry is
Biotechnology Research
Medannex Ltd's top competitors are
Galytx,
Coding Bio,
Cytomos,
Vacv Biotherapeutics,
Lentitek,
Revolver Therapeutics,
Momentous Therapeutics Ltd,
Cell Guidance Systems,
Ingenza Ltd,
Aten Therapeutics Ltd.
Medannex Ltd's categories are Biotechnology Research
Medannex Ltd's founding year is 2009
